Table 2.

Multivariate analysis of patients with MLL-r AML

EFSOS
HR95% CIPHR95% CIP
Age (≥10 y) 1.24 0.72-2.11 .43 2.13 1.15-3.90 .02 
WBC (≥50 × 109/L) 1.46 0.91-2.35 .12 1.37 0.76-2.47 .29 
MLL-MLLT3 0.70 0.31-1.74 .43 1.08 0.38-3.88 .89 
MLL-MLLT10 1.07 0.48-2.60 .88 1.29 0.45-4.67 .65 
MLL-ELL 0.70 0.24-2.03 .51 1.77 0.52-6.97 .37 
MLL-MLLT4 1.63 0.62-4.48 .32 1.99 0.60-7.78 .27 
MLL-MLLT1 2.61 0.96-7.27 .06 1.64 0.41-7.03 .48 
FLT3 mutation 0.76 0.39-1.45 .41 0.52 0.23-1.13 .10 
KRAS mutation 2.21 1.35-3.59 .002 1.85 1.01-3.31 .045 
NRAS mutation 1.02 0.56-1.76 .95 0.89 0.44-1.68 .73 
PTPN11 mutation 1.41 0.57-3.02 .43 0.89 0.26-2.30 .83 
SETD2 mutation 1.09 0.54-2.04 .80 0.94 0.39-2.04 .88 
STAG2 mutation 1.03 0.27-3.26 .96 0.17 0.01-0.93 .04 
CCND3 mutation 0.80 0.26-2.04 .66 1.58 0.43-4.57 .46 
U2AF1 mutation 1.62 0.59-3.75 .32 1.21 0.40-3.02 .71 
Trisomy 8 1.46 0.67-2.88 .32 2.50 1.07-5.32 .04 
EFSOS
HR95% CIPHR95% CIP
Age (≥10 y) 1.24 0.72-2.11 .43 2.13 1.15-3.90 .02 
WBC (≥50 × 109/L) 1.46 0.91-2.35 .12 1.37 0.76-2.47 .29 
MLL-MLLT3 0.70 0.31-1.74 .43 1.08 0.38-3.88 .89 
MLL-MLLT10 1.07 0.48-2.60 .88 1.29 0.45-4.67 .65 
MLL-ELL 0.70 0.24-2.03 .51 1.77 0.52-6.97 .37 
MLL-MLLT4 1.63 0.62-4.48 .32 1.99 0.60-7.78 .27 
MLL-MLLT1 2.61 0.96-7.27 .06 1.64 0.41-7.03 .48 
FLT3 mutation 0.76 0.39-1.45 .41 0.52 0.23-1.13 .10 
KRAS mutation 2.21 1.35-3.59 .002 1.85 1.01-3.31 .045 
NRAS mutation 1.02 0.56-1.76 .95 0.89 0.44-1.68 .73 
PTPN11 mutation 1.41 0.57-3.02 .43 0.89 0.26-2.30 .83 
SETD2 mutation 1.09 0.54-2.04 .80 0.94 0.39-2.04 .88 
STAG2 mutation 1.03 0.27-3.26 .96 0.17 0.01-0.93 .04 
CCND3 mutation 0.80 0.26-2.04 .66 1.58 0.43-4.57 .46 
U2AF1 mutation 1.62 0.59-3.75 .32 1.21 0.40-3.02 .71 
Trisomy 8 1.46 0.67-2.88 .32 2.50 1.07-5.32 .04 

Bold indicates statistical significance (P < .05).

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal